Inhibiting the sEH with small-molecule inhibitors (sEHI) has been found to promote brown adipogenesis and reduce triglycerides in preclinical obesity (Overby et al., 2020). This evidence concerns the gene EPHX2 and obesity due to melanocortin 4 receptor deficiency.